Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 16 of the 62 sources its claims cite were checked for support.
Abstract
Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25 minutes), mainly by vascular transport across the blood-brain barrier (BBB). The efflux transport system for Ass(1-40) at the BBB was half saturated at 15.3 nM, and the maximal transport capacity was reached between 70 nM and 100 nM. Ass(1-40) clearance was substantially inhibited by the receptor-associated protein, and by antibodies against LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M). As compared to adult wild-type mice, clearance was significantly reduced in young and old apolipoprotein E (apoE) knockout mice, and in old wild-type mice. There was no evidence that Ass was metabolized in brain interstitial fluid and degraded to smaller peptide fragments and amino acids before its transport across the BBB into the circulation. LRP-1, although abundant in brain microvessels in young mice, was downregulated in older animals, and this downregulation correlated with regional Ass accumulation in brains of Alzheimer's disease (AD) patients. We conclude that the BBB removes Ass from the brain largely via age-dependent, LRP-1-mediated transport that is influenced by alpha(2)M and/or apoE, and may be impaired in AD.
Overview
CoChat Summary
TL;DR
In mice, intracerebrally injected ¹²⁵I-Aβ1-40 is rapidly cleared from brain, mainly by LRP-1-mediated transport across the blood-brain barrier, with clearance influenced by α2M and apoE. LRP-1 downregulation in older mice and in Alzheimer’s disease brain regions correlates with Aβ accumulation, suggesting impaired vascular clearance may contribute to AD.
Key findings
- After intracerebral microinjection in young mice, total brain efflux half-time for ¹²⁵I-Aβ1-40 was 25.5 ± 2.0 minutes versus 239.0 ± 12.5 minutes for [¹⁴C]inulin (9.4-fold difference); BBB transport accounted for 73.8% of efflux, ISF bulk flow 10.7%, and 15.6% remained retained at 60 nM.
- Aβ1-40 clearance was concentration-dependent, half-saturated at 15.3 nM, and maximal between 70 nM and 100 nM. Anti-LRP-1 antibody inhibited clearance by about 55% (58% at 12 nM and 53% at 60 nM), RAP inhibited by 30–44%, and anti-α2M inhibited by 25%; anti-LRP-2 and anti-RAGE had no effect.
- There was no evidence of significant Aβ1-40 degradation in brain ISF before transport: injected peptide was >97% intact, 93.7% remained intact at 60 minutes, and only 4.2–9.9% of brain ¹²⁵I radioactivity was non-TCA-precipitable within 270 minutes; plasma degradation increased from 37.6% to 58.3% between 15 and 120 minutes.
- Clearance was reduced in apoE knockout and older mice: 30% reduction in young apoE KO mice, about 55% and 40% reductions in 9-month-old wild-type and apoE KO mice at 12 nM, and 46% reduction in 9-month-old apoE KO mice at 60 nM. LRP-1-positive brain vessels dropped from 94% in 2-month-old mice to 52% in 9-month-old mice, and reduced LRP-1 staining in AD frontal cortex correlated with regional Aβ accumulation.
Methods
- Male C57BL/6 wild-type and apoE knockout mice at 8–10 weeks and 9–10 months received intracerebral microinjections into the right caudate nucleus of ¹²⁵I-Aβ1-40 (0.05–120 nM) plus [¹⁴C]inulin; clearance was measured from 10 to 300 minutes, with dose and inhibitor studies at 30 minutes.
- Radioactivity was analyzed by TCA precipitation, HPLC, and SDS-PAGE; compartmental modeling separated BBB transport, ISF bulk flow, and brain retention. Inhibitors included anti-LRP-1 R777, RAP, anti-α2M, anti-LRP-2, anti-RAGE, fucoidin, and BCH.
- Immunocytochemistry was performed in mouse brain and human frontal cortex/cerebellum from 3 AD patients and 3 age-matched controls (postmortem 4–7 hours), using antibodies against LRP-1, α2M, Aβ1-40/1-42, and CD105.
Limitations
- The paper does not state limitations explicitly. Evident from the text: the mouse clearance model uses synthetic ¹²⁵I-Aβ1-40 and intracerebral injection, which may not fully reflect endogenous Aβ production and clearance.
- Evident: human data are correlational and based on only 3 AD patients and 3 controls; LRP-1 involvement is inferred from antibody/RAP inhibition and immunostaining rather than direct transport assays.
- Evident: the identity of an alternative low-concentration BBB transport mechanism remains unknown, α2M staining cannot distinguish circulating from microvessel-associated α2M, and age comparisons are limited to young versus 9-month-old mice.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 21 Not checked · 114 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies from our laboratory and others have demonstrated a major role of the BBB in determining the concentrations of A b in the CNS by regulating transport of circulating A b (33, 39, 49-51, 62-66).”
What the sources say
- Partly supportedcites [33] Mackic, 1998, J Clin Invest sourceExperimental — accuracy not yet measured
The Discussion reports transport of circulating Aβ across a human BBB cell model and says that this transport would tend to increase Aβ accumulation in the brain. It does not demonstrate that the BBB has a major role in determining CNS Aβ concentrations in vivo; the paper describes that broader implication as likely. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s opening summary (page not specified in our copy) reports transport of Aβ–apolipoprotein J complexes across the blood–brain barrier into brain tissue in a guinea pig model. It does not establish that this transport has a major role in determining overall CNS Aβ concentrations, as the citing sentence claims. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [49] Maness, 1994, Life Sci source
- Not checked — no full text of the sourcecites [50] Poduslo, 1997, Neurobiol Dis source
- Not checked — no full text of the sourcecites [51] Martel, 1997, J Neurochem source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Binding/uptake studies in mouse embryonic fibroblasts (wild type and deficient in LRP-1), confirmed that free A b is not a ligand for LRP-1 (37, 45).”
What the sources say
- Partly supportedcites [37] Narita, 1997, J Neurochem sourceExperimental — accuracy not yet measured
The Abstract and Discussion report that free Aβ degradation was not inhibited by RAP and describe it as LRP-independent. But Table 1 tested free Aβ in human U87 glioblastoma cells; the mouse embryonic fibroblast comparison tested Aβ complexed with α2-macroglobulin, not free Aβ. Thus the paper supports the LRP-independent uptake conclusion, but not the claim that the fibroblast studies confirmed it. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [45] Kounnas, 1995, Cell source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because normal aging is associated with A b accumulation in the brain (1)”
What the sources say
- Supportedcites [1] Wisniewski, 1997, Neurobiol Dis source
The section on the amyloid cascade hypothesis says that extensive Aβ-containing preamyloid deposits can be found in aged individuals with no reported clinical symptoms. This supports the claim that brain Aβ accumulation is associated with normal aging; the paper does not say it occurs in every older person. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This makes re-entry of radiolabeled A b into the brain very unlikely, because the blood-to-brain transport of A b normally operates down the concentration gradient (39, 62-65).”
What the sources say
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s study summary (page not identified in our copy) reports transport of Aβ–apolipoprotein J complexes from blood into brain parenchyma. It does not say that this transport normally follows a concentration gradient or that re-entry of radiolabeled Aβ is unlikely. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [62] Zlokovic, 1993, Biochem Biophys Res Commun source
- Not checked — no full text of the sourcecites [63] Ghilardi, 1996, Neuroreport source
- Not checked — no full text of the sourcecites [64] Shayo, 1997, Life Sci source
- Partly supportedcites [65] Martel, 1996, Neurosci Lett sourceExperimental — accuracy not yet measured
The discussion passage in our copy (labeled Abstract; page unavailable) says that a lower soluble Aβ42 concentration on the brain side of the BBB would provide a thermodynamic impetus for transport from capillaries into brain. It does not establish that blood-to-brain transport normally operates down a concentration gradient or that re-entry of radiolabeled Aβ is very unlikely; the study also observed uptake of radiolabeled Aβ in perfused guinea-pig brains. (LLM, conf=0.80)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RAP, a chaperone protein that facilitates proper folding and subsequent trafficking of LRP-1 and LRP-2 (69), also inhibited A b clearance.”
What the sources say
- Partly supportedcites [69] Bu, 1996, J Biol Chem sourceExperimental — accuracy not yet measured
The citation is attached to the description of RAP as a folding and trafficking chaperone, not to the citing authors’ statement that RAP inhibited Aβ clearance. The paper’s Discussion supports that role for LRP, but does not establish it for the separate receptor LRP-2; its use of “LRP2” denotes a domain of LRP. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
92 more claims
Create a free account to see all 147 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, transport studies using radiolabeled and unlabeled Alzheimer's A 𝛃 peptide have shown that under physiological conditions, the perivascular ISF flow contributes to 15-20% of A 𝛃 clearance from the mouse brain (58, 535, 659), whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 binds Alzheimer's A 𝛃 toxin and mediates its brain-to-blood clearance (58, 137, 535, 561).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several groups have reported that trans-BBB efflux of Aβ into peripheral blood circulation is one of the main pathways of physiological clearance with ApoE, ApoJ, and ApoA1 as chaperones27,31,32.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 and LRP2 are expressed in brain endothelium and colocalize mainly on the abluminal side of the BBB in humans and rodents (137, 404, 535, 607, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“The HPLC analysis of brain radioactivity confirmed the TCA results by indicating that 93.7% of the peptide remains intact in brain ISF at 60 minutes (Figure 3b, right).”
§ Figure 3 · p. 6
“( b ) Left panel shows HPLC elution profile of brain tissue 60 minutes after intracerebral microinjection of 125 I-A b 1-40 (60 nM). Separation was performed for 30 mg of brain tissue on a reverse-phase HPLC column, using a 30-minute linear gradient of 25-83% acetonitrile in 0.1% TFA, pH 2. 125 I-A b 1-40 eluted at 52%, corresponding to the elution time of A b 1-40 standard. Right panel shows SDS-PAGE analysis”
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 10×
“No anti-Aβ1-40–positive or Aβ1-42–positive staining was seen in either AD or control tissues.”
BackgroundInfluentialCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 2×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 9×
“In contrast, anti–LRP-2 Ab (Figure 4b) and anti-RAGE Ab (Figure 4c) did not affect Aβ clearance.”
BackgroundInfluentialIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundSelf-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 1×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundAlzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · cited 8×
“However, the physiological relevance of the proposed degradation mechanism for Aβ1-42 (28) remains unclear, because the peptide was studied at extremely high concentrations (∼ 240 μM) that are not found even in brains with severe β-amyloidosis (30).”
BackgroundMethodResultInfluentialThe cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
Background
Research works printed but not linked: 4
- Suzuki, 1994, Am J Pathol, 145, 452
- Urmoneit, 1997, Lab Invest, 77, 157
- Yamada, 1991, Am J Physiol, 261, H1197
- Kounnas, 1994, In Vivo, 8, 343
Cited by
Items 101–200 of 1,448
Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
“Aβ can enter peripheral circulation through various routes, such as transfer across the blood-brain barrier, the glymphatic system, or perivascular drainage (Shibata et al., 2000; Weller et al., 2008; Iliff et al., 2012; Iliff and Nedergaard, 2013).”
BackgroundSimon, M., Wang, M. X., Ismail, O., Braun, M., Schindler, A. G., Reemmer, J., Wang, Z., Haveliwala, M. A., O’Boyle, R. P., Han, W. Y., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00999-5 · Cited by 271
“Interstitial Aβ is cleared locally through cellular uptake and degradation [5–8], efflux across the blood-brain barrier [9, 10], and through clearance by the glymphatic system which supports exchange to the cerebrospinal fluid (CSF) compartment along perivascular pathways [11, 12].”
BackgroundFagan, A. M., Watson, M., Parsadanian, M., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0483 · Cited by 290
Self-citationCerebral small vessel disease: Capillary pathways to stroke and cognitive decline
Østergaard, L., Engedal, T. S., Moreton, F., Hansen, M. B., Wardlaw, J. M., Dalkara, T., Markus, H. S., & Muir, K. W. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15606723 · Cited by 283
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
“Apoε4 may also promote damage to the BBB by upregulation of pro-inflammatory signaling through cyclophilin A [153].”
BackgroundResultInfluentialThe Pericyte: A Forgotten Cell Type with Important Implications for Alzheimer's Disease?
Winkler, E. A., Sagare, A. P., & Zlokovic, B. V. (2014) · Brain Pathology · doi:10.1111/bpa.12152 · Cited by 278
“The predominate clearance protein—low-density lipoprotein receptor-related protein-1 (LRP-1)—binds Aβ on its abluminal plasma membrane and initiates its clearance to blood, as shown in multiple animal models (13, 39, 78, 149) and in vitro BBB models (39, 110, 184).”
Jaeger, L. B., Dohgu, S., Sultana, R., Lynch, J. L., Owen, J. B., Erickson, M. A., Shah, G. N., Price, T. O., Fleegal-Demotta, M. A., Butterfiled, D. A., et al. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.01.017 · Cited by 281
“Ab is transported by RAGE (receptor for advanced glycation end products) into (Martel et al., 1996; Bell et al., 2006; Deane et al., 2003; Maness et al., 1994) and by LRP-1 (low density lipoprotein receptor-related protein-1) out of (Banks et al., 2003; Deane et al., 2004a; Shibata et al., 2000; Ghersi-Egea et al., 19…”
BackgroundMa, Q., Zhao, Z., Sagare, A. P., Wu, Y., Wang, M., Owens, N. C., Verghese, P. B., Herz, J., Holtzman, D. M., & Zlokovic, B. V. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0286-0 · Cited by 281
Self-citationKanekiyo, T., & Bu, G. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00093 · Cited by 281
“Immunohistochemical analysis also showed that LRP1-positive vessels were reduced in patients with AD (Shibata et al., 2000) and cerebrovascular β-amyloidosis Dutch-type compared to controls (Deane et al., 2004), although there are also conflicting reports (Donahue et al., 2006; Wilhelmus et al.,…”
BackgroundResultRole of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease
Wu, Z., Guo, H., Chow, N., Sallstrom, J., Bell, R. D., Deane, R., Brooks, A. I., Kanagala, S., Rubio, A., Sagare, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1287 · Cited by 280
Neuronal Clearance of Amyloid-β by Endocytic Receptor LRP1
Kanekiyo, T., Cirrito, J. R., Liu, C.-C., Shinohara, M., Li, J., Schuler, D. R., Shinohara, M., Holtzman, D. M., & Bu, G. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.3487-13.2013 · Cited by 280
“It has been shown that clearance of exogenous A from the brain is suppressed by LRP1 antagonist, RAP, or antibodies against LRP1 (Shibata et al., 2000).”
BackgroundSelf-citationKoldamova, R. P., Lefterov, I. M., Staufenbiel, M., Wolfe, D., Huang, S., Glorioso, J. C., Walter, M., Roth, M. G., & Lazo, J. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411420200 · Cited by 279
Kook, S.-Y., Hong, H. S., Moon, M., Ha, C. M., Chang, S., & Mook-Jung, I. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.6102-11.2012 · Cited by 265
“Also, the influx of A across the BBB depends on its interaction with RAGE (Mackic et al., 1998), and RAGE and LRP-1 have been proposed to stabilize A concentrations in the plasma and brain through the BBB (Shibata et al., 2000).”
BackgroundInfluentialGovindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
“The mechanism most frequently cited is the downregulation of LRP1, the major endothelial cell surface receptor responsible for the transcytosis of Aβ out of the brain across the BBB [251].”
BackgroundFryer, J. D., Simmons, K., Parsadanian, M., Bales, K. R., Paul, S. M., Sullivan, P. M., & Holtzman, D. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5170-04.2005 · Cited by 278
“The local environment along these pathways has abundant molecules known to bind apoE, such as heparan sulfate proteoglycans and low-density lipoprotein receptor family members (Shibata et al., 2000; Strittmatter and Bova Hill, 2002).”
BackgroundSelf-citationXiang, Y., Bu, X.-L., Liu, Y.-H., Zhu, C., Shen, L.-L., Jiao, S.-S., Zhu, X.-Y., Giunta, B., Tan, J., Song, W.-H., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1477-1 · Cited by 277
Strazielle, N., & Ghersi-Egea, J. F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300518e · Cited by 263
Hay, J. R., Johnson, V. E., Young, A. M. H., Smith, D. H., & Stewart, W. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/74.12.1147 · Cited by 265
Heme scavenging and the other facets of hemopexin
Tolosano, E., Fagoonee, S., Morello, N., Vinchi, F., & Fiorito, V. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2787 · Cited by 272
“Previous studies demonstrated that LRP1 is expressed in brain and, in particular, in epithelial cells of choroid plexi, endothelial cells of microvessels, neurons, perivascular astrocytes, and microglial cells (31, 100, 135), thus supporting the possibility that Hx acts at multiple sites, as presented in Fig.”
Clusterin: A forgotten player in Alzheimer's disease
Nuutinen, T., Suuronen, T., Kauppinen, A., & Salminen, A. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.007 · Cited by 267
Verdier, Y., Zarándi, M., & Penke, B. (2004) · Journal of Peptide Science · doi:10.1002/psc.573 · Cited by 262
“LRP and its ligands (ApoE-containing lipoproteins, activated α2-macroglobulin complexes and APP) have all been genetically linked to AD and are colocalized in senile plaques (for a review, see [122].”
BackgroundAbuznait, A. H., Qosa, H., Busnena, B. A., El Sayed, K. A., & Kaddoumi, A. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400024q · Cited by 259
Aβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
“The best characterized of these are illustrated in this diagram: enzymatic degradation within the brain parenchyma (17Y19); perivascular drainage of AA along basement membranes to cervical lymph nodes and into the cerebrospinal fluid (9, 10, 20); transport across vessel walls into the circulation, mediated by binding…”
BackgroundInterstitial fluid drainage is impaired in ischemic stroke and Alzheimer’s disease mouse models
Arbel-Ornath, M., Hudry, E., Eikermann-Haerter, K., Hou, S., Gregory, J. L., Zhao, L., Betensky, R. A., Frosch, M. P., Greenberg, S. M., & Bacskai, B. J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1145-2 · Cited by 257
“Late onset sporadic AD in particular, which accounts for the vast majority of cases, is thought to be associated with failure to clear the peptide from the aging brain [10, 33].”
BackgroundSRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells
Bell, R. D., Deane, R., Chow, N., Long, X., Sagare, A., Singh, I., Streb, J. W., Guo, H., Rubio, A., Van Nostrand, W., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1819 · Cited by 261
“The low-density lipoprotein receptor-related protein 1 (LRP) is a major Aβ clearance receptor at the BB”
BackgroundZlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261
“In addition to regulating Ab clearance from brain (Shibata et al. 2000; Deane et al. 2004a; see below), it has been shown that the LRP1 cytoplasmic C-terminal domain interacts with Ab-precursor protein’s (APP) cytoplasmic domain via FE65, an LRP1 adaptor protein, which in turn influences APP…”
InfluentialSigurdsson, E. M., Scholtzova, H., Mehta, P. D., Frangione, B., & Wisniewski, T. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61715-4 · Cited by 258
Self-citationAmyloid-β Receptors: The Good, the Bad, and the Prion Protein
Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V., & Hooper, N. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.702704 · Cited by 256
“The low-density lipoprotein receptor (LDLR) is also implicated in neuronal and astrocytic A uptake and BBB transcytosis of A (30).”
BackgroundInfluentialCerebrospinal fluid regulates skull bone marrow niches via direct access through dural channels
Mazzitelli, J. A., Smyth, L. C. D., Cross, K. A., Dykstra, T., Sun, J., Du, S., Mamuladze, T., Smirnov, I., Rustenhoven, J., & Kipnis, J. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01029-1 · Cited by 250
DeMattos, R. B., Bales, K. R., Parsadanian, M., O'Dell, M. A., Foss, E. M., Paul, S. M., & Holtzman, D. M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00889.x · Cited by 258
Self-citationNeuroinflammation: A Common Pathway in CNS Diseases as Mediated at the Blood-Brain Barrier
Erickson, M. A., Dohi, K., & Banks, W. A. (2012) · Neuroimmunomodulation · doi:10.1159/000330247 · Cited by 246
Brain borders at the central stage of neuroimmunology
Rustenhoven, J., & Kipnis, J. (2022) · Nature · doi:10.1038/s41586-022-05474-7 · Cited by 253
Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251
“2006) and Ab cerebrovascular and brain accumulation in AD patients (Shibata et al. 2000; Donahue et al. 2006).”
BackgroundMethodDoes vascular pathology contribute to Alzheimer changes?
Kalaria, R. N., Akinyemi, R., & Ihara, M. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.07.032 · Cited by 239
“the advanced glycation end product receptor (RAGE) [71] in ageing rodents, non‐human primates and AD patients [72,73] handling amyloid β peptides across a defective BBB would compromise the homeostasis of the cerebral microenvironment and increase oxidative and nitrosative damage as well as protease activity (Fig.”
BackgroundDinkins, M. B., Enasko, J., Hernandez, C., Wang, G., Kong, J., Helwa, I., Liu, Y., Terry, A. V., & Bieberich, E. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1429-16.2016 · Cited by 245
“If the total EV levels are reduced, a larger proportion of A remains soluble and easier to clear by either glia or LRP1-mediated transport across the BBB (Shibata et al., 2000; Deane et al., 2008; Storck et al., 2016).”
BackgroundHartz, A. M. S., Bauer, B., Soldner, E. L. B., Wolf, A., Boy, S., Backhaus, R., Mihaljevic, I., Bogdahn, U., Klünemann, H. H., Schuierer, G., et al. (2012) · Stroke · doi:10.1161/strokeaha.111.627562 · Cited by 248
Evidence for impaired amyloid β clearance in Alzheimer's disease
Wildsmith, K. R., Holley, M., Savage, J. C., Skerrett, R., & Landreth, G. E. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt187 · Cited by 236
Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247
Brain Microvascular Pericytes in Vascular Cognitive Impairment and Dementia
Uemura, M. T., Maki, T., Ihara, M., Lee, V. M. Y., & Trojanowski, J. Q. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00080 · Cited by 237
“Aβ clearance by pericytes is mainly performed through receptor-mediated endocytic pathways, especially low-density lipoprotein receptorrelated protein 1 (LRP-1) (Shibata et al., 2000; Zlokovic et al., 2010; Ma et al., 2018).”
BackgroundPreston, S. D., Steart, P. V., Wilkinson, A., Nicoll, J. A. R., & Weller, R. O. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00424.x · Cited by 239
Huang, Y., Weisgraber, K. H., Mucke, L., & Mahley, R. W. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:189 · Cited by 242
“…al., 1994; Sanan et al., 1994; Wisniewski et al., 1994; Martel et al., 1997; Bales et al., 1999; Holtzman et al., 2000a, 2000b; Irizarry et al., 2000; Shibata et al., 2000), impairment of the antioxidative defense system (Miyata and Smith, 1996; Lauderback et al., 2002; Mazur-Kolecka et al.,…”
BackgroundBlood-brain barrier alterations in ageing and dementia
Popescu, B. O., Toescu, E. C., Popescu, L. M., Bajenaru, O., Muresanu, D. F., Schultzberg, M., & Bogdanovic, N. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.02.321 · Cited by 236
Targeting Neuroinflammation to Treat Alzheimer’s Disease
Ardura-Fabregat, A., Boddeke, E. W. G. M., Boza-Serrano, A., Brioschi, S., Castro-Gomez, S., Ceyzériat, K., Dansokho, C., Dierkes, T., Gelders, G., Heneka, M. T., et al. (2017) · CNS Drugs · doi:10.1007/s40263-017-0483-3 · Cited by 233
Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms
Attems, J. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1074-9 · Cited by 242
“As indicated by animal studies (wild-type and APP transgenic mice), clearance via the perivascular pathway becomes more significant with age [61, 118].”
BackgroundDeane, R., Sagare, A., Hamm, K., Parisi, M., LaRue, B., Guo, H., Wu, Z., Holtzman, D. M., & Zlokovic, B. V. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3697-05.2005 · Cited by 233
“By using a brain clearance method (Shibata et al., 2000), we showed that efflux of centrally administered 125I-A 40 from mouse brain ISF determined over 30 min was moderately but significantly increased by 15% at 1 h of peripheral 4G8 intraperitoneal administration (Fig.”
BackgroundMethodInfluentialSelf-citationCholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease
Martins, I. J., Berger, T., Sharman, M. J., Verdile, G., Fuller, S. J., & Martins, R. N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06408.x · Cited by 232
Kuhnke, D., Jedlitschky, G., Grube, M., Krohn, M., Jucker, M., Mosyagin, I., Cascorbi, I., Walker, L. C., Kroemer, H. K., Warzok, R. W., et al. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00075.x · Cited by 226
“The present study supports the hypothesis that P-gp plays a key role in the clearance of Aβ from the brain via the BBB, and therefore might be causally involved in the Amyloid-β Transport by P-glycoprotein—Kuhnke et al 353 © 2007 The Authors Journal Compilation © 2007 International Society of Neuropathology • Brain Pa…”
BackgroundInfluentialIdentification of early pericyte loss and vascular amyloidosis in Alzheimer’s disease retina
Shi, H., Koronyo, Y., Rentsendorj, A., Regis, G. C., Sheyn, J., Fuchs, D.-T., Kramerov, A. A., Ljubimov, A. V., Dumitrascu, O. M., Rodriguez, A. R., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02134-w · Cited by 230
Self-citationCholesterol homeostasis in neurons and glial cells
Vance, J. E., Hayashi, H., & Karten, B. (2005) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2005.01.005 · Cited by 224
Ling, Y., Morgan, K., & Kalsheker, N. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00133-x · Cited by 224
High transcytosis of melanotransferrin (P97) across the blood–brain barrier
Demeule, M., Poirier, J., Jodoin, J., Bertrand, Y., Desrosiers, R. R., Dagenais, C., Nguyen, T., Lanthier, J., Gabathuler, R., Kennard, M., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01201.x · Cited by 221
“P97 and other LRP ligands [amyloid-b peptide (Ab)1)40, apolipoprotein E (apoE) and activated a2-macroglobulin (a2M)] have been reported to accumulate during Alzheimer’s disease (Jefferies et al. 1996; Shibata et al. 2000; Qiu et al. 2001).”
BackgroundEndocannabinoid system in neurodegenerative disorders
Basavarajappa, B. S., Shivakumar, M., Joshi, V., & Subbanna, S. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14098 · Cited by 212
“Activation of CB1Rs or inhibition of endocannabinoid-degrading enzymes [FAAH, MAGL, and alpha/beta-Hydrolase domain containing 6 (ABHD6)] was shown to enhance Ab clearance across the blood-brain barrier through increased expression of the low-density lipoprotein receptor-related protein 1 (LRP1) (Shibata et al. 2000).”
BackgroundInfluentialFoster, P. P., Rosenblatt, K. P., & Kuljiš, R. O. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00028 · Cited by 198
“…and Topol, 2004; Roher et al., 2004; Honig et al., 2005; Utter et al., 2008); (3) angiogenesis deficiency (Paris et al., 2004; Wu et al., 2005), and (4) deficiency of Aβ clearance across the blood–brain barrier (Shibata et al., 2000, 2008; Carro et al., 2002, 2003, 2005, 2006b; Trejo et al., 2004).”
BackgroundDural lymphatics regulate clearance of extracellular tau from the CNS
Patel, T. K., Habimana-Griffin, L., Gao, X., Xu, B., Achilefu, S., Alitalo, K., McKee, C. A., Sheehan, P. W., Musiek, E. S., Xiong, C., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0312-x · Cited by 216
Self-citationKrol, S., Macrez, R., Docagne, F., Defer, G., Laurent, S., Rahman, M., Hajipour, M. J., Kehoe, P. G., & Mahmoudi, M. (2013) · Chemical Reviews · doi:10.1021/cr200472g · Cited by 216
Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease
Farfara, D., Lifshitz, V., & Frenkel, D. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00314.x · Cited by 216
“LRP is expressed in reactive astrocytes and in the brain capillary endothelium [99, 100].”
BackgroundSiemers, E., Skinner, M., Dean, R. A., Gonzales, C., Satterwhite, J., Farlow, M., Ness, D., & May, P. C. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000167360.27670.29 · Cited by 216
“An active transport system for Ab from brain to plasma has been demonstrated.(33,34) While the levels of Ab, including Ab1-42, increase substantially in the brains of patients with AD, the concentration of Ab1-42 in CSF TABLE 3.”
BackgroundXiong, H., Callaghan, D., Jones, A., Bai, J., Rasquinha, I., Smith, C., Pei, K., Walker, D., Lue, L.-F., Stanimirovic, D., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5103-08.2009 · Cited by 202
“In addition, abluminal LRP-1, sLRP, ApoE2/E3, and ApoJ have also been implicated in the clearance of A peptides from the brain (Shibata et al., 2000; Deane et al., 2004a, 2008a,b; Bell et al., 2007; Sagare et al., 2007) (Fig.”
BackgroundBlood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216288 · Cited by 212
“The dysregulation of LRP1 in AD patients’ brain vasculature and parenchyma has implications for the clearance and accumulation of A β peptides, critical players in the disease’s pathogenesis [196].”
BackgroundCerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases
Grammas, P., Martinez, J., & Miller, B. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001918 · Cited by 202
“83 Shibata, M. et al. (2000) Clearance of Alzheimer’s amyloid β(1-40) peptide from brain by LDL”
BackgroundHuynh, T.-P. V., Davis, A. A., Ulrich, J. D., & Holtzman, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075481 · Cited by 210
“Mechanistic studies linking apoE to A transport from the ISF have identified a number of involved transporters, including P-glycoprotein (88), LDL receptor-related protein 1 (LRP1) (92), and LDL receptor (LDLR) (102).”
BackgroundInfluentialSelf-citationSystemic Catabolism of Alzheimer's Aβ40 and Aβ42
Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., & Frangione, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407668200 · Cited by 209
Self-citationRegulation of the Blood–Brain Barrier by Circadian Rhythms and Sleep
Cuddapah, V. A., Zhang, S. L., & Sehgal, A. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.05.001 · Cited by 200
“β-amyloid is cleared through multiple overlapping routes (previously reviewed in detail [49]), which include substantial clearance through the BBB [50, 51], as well as elimination through the interstitital fluid-CSF exchange described above [33].”
BackgroundNaert, G., & Rivest, S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0299-11.2011 · Cited by 207
“…based on the findings of active A transport from the CNS into the periphery across the blood– brain barrier via the low-density lipoprotein receptor (Deane et al., 2004), and from the periphery into CNS via the receptor for advanced glycation end products (Shibata et al., 2000; Deane et al., 2003).”
BackgroundCarare, R. O., Hawkes, C. A., Jeffrey, M., Kalaria, R. N., & Weller, R. O. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12042 · Cited by 207
Cell-Culture Models of the Blood–Brain Barrier
He, Y., Yao, Y., Tsirka, S. E., & Cao, Y. (2014) · Stroke · doi:10.1161/strokeaha.114.005427 · Cited by 194
Relationship Between Amyloid-β Deposition and Blood–Brain Barrier Dysfunction in Alzheimer’s Disease
Wang, D., Chen, F., Han, Z., Yin, Z., Ge, X., & Lei, P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.695479 · Cited by 197
Hladky, S. B., & Barrand, M. A. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0113-6 · Cited by 206
“[62] found that the half-life of inulin was shorter than expected and Groothuis et al.”
BackgroundInfluentialMechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease
Yoon, S.-S., & AhnJo, S.-M. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.3.245 · Cited by 205
“…is mediated by a series of clearance receptors such as low-density lipoprotein receptor-related protein 1 (LRP1), very low-density lipoprotein receptor (VLDLR) and P-glycoprotein localized predominantly on the abluminal side of the cerebral endothelium (Shibata et al., 2000; Deane et al., 2004).”
BackgroundRamanathan, A., Nelson, A. R., Sagare, A. P., & Zlokovic, B. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00136 · Cited by 205
“Expression Levels LRP1 expression levels are significantly reduced in brain endothelial cells in normally aging and AD humans and animal models (Kang et al., 2000; Shibata et al., 2000; Deane et al., 2004; Donahue et al., 2006) leading to higher levels of Aβ in the brain (Figure 3A).”
BackgroundInfluentialSporadic and Familial Cerebral Amyloid Angiopathies
Revesz, T., Holton, J. L., Lashley, T., Plant, G., Rostagno, A., Ghiso, J., & Frangione, B. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00449.x · Cited by 199
Self-citationThe capillary dysfunction hypothesis of Alzheimer's disease
Østergaard, L., Aamand, R., Gutiérrez-Jiménez, E., Ho, Y.-C. L., Blicher, J. U., Madsen, S. M., Nagenthiraja, K., Dalby, R. B., Drasbek, K. R., Møller, A., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.09.011 · Cited by 199
“Pericytes are believed to come in close contact with amyloid, both during the normal clearance of soluble amyloid during transport across the BBB and during its perivascular removal (Ball et al., 2010; Shibata et al., 2000;Weller et al., 2008).”
InfluentialClearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives
Wang, Y.-J., Zhou, H.-D., & Zhou, X.-F. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.08.004 · Cited by 205
Total Aβ 42 /Aβ 40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
Doecke, J. D., Pérez-Grijalba, V., Fandos, N., Fowler, C., Villemagne, V. L., Masters, C. L., Pesini, P., Sarasa, M., & for the AIBL Research Group (2020) · Neurology · doi:10.1212/wnl.0000000000009240 · Cited by 193
Age-Associated Changes in the Immune System and Blood–Brain Barrier Functions
Erickson, M. A., & Banks, W. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071632 · Cited by 198
“LRP-1 expression was shown to be decreased in brain microvessels with age, and in AD [110,113].”
BackgroundPietrzik, C. U., Busse, T., Merriam, D. E., Weggen, S., & Koo, E. H. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf568 · Cited by 198
Cheng, Y., Tian, D.-Y., & Wang, Y.-J. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00195-1 · Cited by 190
“Aβ efflux is normally mediated via its receptors on the brain endothelium, and the clearance mechanism is mainly mediated by cell surface proteins, mainly low density lipoprotein receptor-related protein 1 (LRP1), which localizes predominantly on the abluminal side of the cerebral endothelium [11].”
Hippocampal RAGE immunoreactivity in early and advanced Alzheimer’s disease
Miller, M. C., Tavares, R., Johanson, C. E., Hovanesian, V., Donahue, J. E., Gonzalez, L., Silverberg, G. D., & Stopa, E. G. (2008) · Brain Research · doi:10.1016/j.brainres.2008.06.124 · Cited by 194
“…in direct contrast to the outward-going movement of Aβ from the brain, across the bloodbrain barrier, and into the plasma by way of other well-known receptors such as the low density lipoprotein receptor-related protein 1 (LRP-1) and P-glycoprotein (P-gp) [Shibata et al. 2000, Cirrito et al. 2005].”
BackgroundCerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice
Krohn, M., Lange, C., Hofrichter, J., Scheffler, K., Stenzel, J., Steffen, J., Schumacher, T., Brüning, T., Plath, A.-S., Alfen, F., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57867 · Cited by 183
“ABCG2 is upregulated in Alzheimer’s brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta (1-40) peptides.”
BackgroundShao, K., Huang, R., Li, J., Han, L., Ye, L., Lou, J., & Jiang, C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.06.018 · Cited by 191
Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging
Silverberg, G. D., Messier, A. A., Miller, M. C., Machan, J. T., Majmudar, S. S., Stopa, E. G., Donahue, J. E., & Johanson, C. E. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181f46e25 · Cited by 191
“Blood-brain barrier transport of AA out of the ISF across the BBB occurs via a basal endothelial receptor, the low-density lipoprotein receptorYrelated protein 1 (LRP-1) (17, 23), and via the apical (luminal) transporter P-glycoprotein (P-gp) (24, 25).”
BackgroundYan, H., Wang, L., Wang, J., Weng, X., Lei, H., Wang, X., Jiang, L., Zhu, J., Lu, W., Wei, X., et al. (2012) · ACS Nano · doi:10.1021/nn203749v · Cited by 191
Phase I Study of GRN1005 in Recurrent Malignant Glioma
Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2481 · Cited by 190
Deane, R., Sagare, A., & Zlokovic, B. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784705487 · Cited by 183
Morris, M. E., Rodriguez-Cruz, V., & Felmlee, M. A. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0110-8 · Cited by 174
“DecreasedPgp expression has been associated with accumulation of Aβ and age progression, confirming the role of this transporter at the BBB (8,144,145).”
BackgroundMontagne, A., Nikolakopoulou, A. M., Huuskonen, M. T., Sagare, A. P., Lawson, E. J., Lazic, D., Rege, S. V., Grond, A., Zuniga, E., Barnes, S. R., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00073-z · Cited by 188
Formation and function of apolipoprotein E-containing lipoproteins in the nervous system
Vance, J. E., & Hayashi, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.007 · Cited by 155
Extracellular Chaperones and Proteostasis
Wyatt, A. R., Yerbury, J. J., Ecroyd, H., & Wilson, M. R. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-072711-163904 · Cited by 183
Versele, R., Sevin, E., Gosselet, F., Fenart, L., & Candela, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810235 · Cited by 171
“Whereas RAGE mediates Aβ peptide entrance from the blood [4,5], LRP1 is mainly involved in Aβ peptide efflux from the brain [6].”
BackgroundInfluentialPatel, J. P., & Frey, B. N. (2015) · Neural Plasticity · doi:10.1155/2015/708306 · Cited by 177
“[53] M.”
BackgroundHow Do Meningeal Lymphatic Vessels Drain the CNS?
Raper, D., Louveau, A., & Kipnis, J. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.07.001 · Cited by 179
“Previous studies have demonstrated that around 85% of Ab is eliminated from the brain by transvascular clearance under normal physiological conditions in mice, while a smaller percentage is cleared by the other routes, notably ISF bulk flow [44,45].”
BackgroundAlzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses
(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183
“C99 then undergoes the cleavage by γ-secretase within the transmembrane domain, leading to the creation of Aβ peptides and the AICD [18].”
BackgroundVascular contributions to Alzheimer's disease
Eisenmenger, L. B., Peret, A., Famakin, B. M., Spahic, A., Roberts, G. S., Bockholt, J. H., Johnson, K. M., & Paulsen, J. S. (2023) · Translational Research · doi:10.1016/j.trsl.2022.12.003 · Cited by 169
Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology?a pilot study
Attems, J., & Jellinger, K. A. (2004) · Acta Neuropathologica · doi:10.1007/s00401-003-0796-9 · Cited by 181
Kumar-Singh, S., Pirici, D., McGowan, E., Serneels, S., Ceuterick, C., Hardy, J., Duff, K., Dickson, D., & Van Broeckhoven, C. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62995-1 · Cited by 184
“Additionally, RAGE can transport A from the blood to the abluminal endothelial surface(55) and further the growth of plaques especially when the normal brain to vessel clearance gradient is lost as can occur during aging.(52) Another factor that could lead to disruption of A clearance is down-regulation of LRP express…”
BackgroundInfluentialEffects of in vivo conditions on amyloid aggregation
Owen, M. C., Gnutt, D., Gao, M., Wärmländer, S. K. T. S., Jarvet, J., Gräslund, A., Winter, R., Ebbinghaus, S., & Strodel, B. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00034d · Cited by 182
Sandsmark, D. K., Bashir, A., Wellington, C. L., & Diaz-Arrastia, R. (2019) · Neuron · doi:10.1016/j.neuron.2019.06.002 · Cited by 178
Boespflug, E. L., & Iliff, J. J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.11.031 · Cited by 168
Biogenesis and metabolism of Alzheimer’s disease Aβ amyloid peptides
Evin, G., & Weidemann, A. (2002) · Peptides · doi:10.1016/s0196-9781(02)00063-3 · Cited by 170
Neuronal Activity Regulates Blood-Brain Barrier Efflux Transport through Endothelial Circadian Genes
Pulido, R. S., Munji, R. N., Chan, T. C., Quirk, C. R., Weiner, G. A., Weger, B. D., Rossi, M. J., Elmsaouri, S., Malfavon, M., Deng, A., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.002 · Cited by 177
“…Pgp function in the brain (Van Assema et al., 2012; Deo et al., 2014), and A β has been shown to be cleared from the brain to the blood through abluminal LRP1 and luminal Pgp (Shibata et al., 2000; Cirrito et al., 2005; Pflanzner et al., 2011, 2012; Zhao et al., 2015; Bruckmann et al., 2016).”
Metadata
- Authors
- Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- NYU Langone Health (US)
- Washington University in St. Louis (US)
- American Red Cross (US)
- University of Rochester Medicine (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2000-12-15
- Volume
- 106
- Issue
- 12
- Pages
- 1489-1499
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC387254
- OpenAlex
- W1997822484
- Cited by
- 1,413
- References
- 76
- Citations by year
- 2026: 38 · 2025: 60 · 2024: 58 · 2023: 59 · 2022: 57 · 2021: 75 · 2020: 85 · 2019: 73 · 2018: 52 · 2017: 67 · 2016: 64 · 2015: 56 · 2014: 60 · 2013: 62 · 2012: 60
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ag016223-04)
- National Institute on Aging (R37AG005891, R01AG013956, P50AG005142, AG16223, R37AG013956, AG05891)
- National Heart, Lung, and Blood Institute (R01HL050784)
- National Institute of Neurological Disorders and Stroke (NS 33466, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Aβ40, Alzheimer's disease, blood-brain barrier, LDL receptor-related protein 1, receptor-associated protein, alpha2-macroglobulin, apolipoprotein E, amyloid-beta clearance, efflux transport, cerebral microvasculature, amyloid-beta deposition
- MeSH terms
- Aging, alpha-Macroglobulins, Alzheimer Disease, Amino Acid Sequence, Animals, Apolipoproteins E, Biological Transport, Blood-Brain Barrier, Brain, Catheterization, Genotype, Half-Life, Humans, Immunohistochemistry, Inulin, Iodine Radioisotopes, Kinetics, Male, Mice, Inbred C57BL, Molecular Sequence Data, Peptide Fragments, Receptors, Immunologic, Amyloid beta-Peptides, Mice, Knockout, Low Density Lipoprotein Receptor-Related Protein-1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






